Bausch Health Companies Inc. Increase (Decrease) in Accounts Payable
Bausch Health Companies Inc. (BHC) reported Increase (Decrease) in Accounts Payable of -$9.92 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2012-05-04
- Bausch Health Companies Inc. increase (decrease) in accounts payable for the quarter ending 2012-03-31 was -$9.92M.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for the quarter ending 2011-12-31 was -$15.48M.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for the quarter ending 2011-09-30 was $16.81M, a 24.55% decline year-over-year.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for the quarter ending 2011-06-30 was $27.50M.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for fiscal 2011 was -$8.98M.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for fiscal 2010 was -$76.10M, a 347.31% decline from fiscal 2009.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for fiscal 2009 was $30.77M.
- Bausch Health Companies Inc. increase (decrease) in accounts payable for fiscal 2008 was -$6.13M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2012-03-31 | -$9.92M 10-Q · filed 2012-05-04 | -$25.40M derived: sum of 2 quarters · filed 2012-05-04 | -$8.59M derived: sum of 3 quarters · filed 2012-05-04 | $18.91M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | -$15.48M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $1.33M derived: sum of 2 quarters · filed 2012-02-29 | $28.83M derived: sum of 3 quarters · filed 2012-02-29 | -$8.98M 10-K · filed 2012-02-29 |
| 2011-09-30 | $16.81M 10-Q · filed 2011-11-04 | $44.30M derived: sum of 2 quarters · filed 2011-11-04 | $6.50M 10-Q · filed 2011-11-04 | -$61.58M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | $27.50M 10-Q · filed 2011-08-08 | -$10.31M 10-Q · filed 2011-08-08 | -$78.39M derived: sum of 3 quarters · filed 2012-05-04 | -$56.11M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | -$37.81M 10-Q · filed 2012-05-04 | -$105.89M derived: sum of 2 quarters · filed 2012-05-04 | -$83.61M derived: sum of 3 quarters · filed 2012-05-04 | -$84.18M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | -$68.08M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$45.80M derived: sum of 2 quarters · filed 2012-02-29 | -$46.37M derived: sum of 3 quarters · filed 2012-02-29 | -$76.10M 10-K · filed 2012-02-29 |
| 2010-09-30 | $22.28M 10-Q · filed 2011-11-04 | $21.71M derived: sum of 2 quarters · filed 2011-11-04 | -$8.02M 10-Q · filed 2011-11-04 | $26.09M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | -$566.00K 10-Q · filed 2011-08-08 | -$30.30M 10-Q · filed 2011-08-08 | $3.81M derived: sum of 3 quarters · filed 2012-02-29 | $10.59M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | -$29.73M 10-Q · filed 2011-05-10 | $4.38M derived: sum of 2 quarters · filed 2012-02-29 | $11.15M derived: sum of 3 quarters · filed 2012-02-29 | $17.38M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $34.11M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $40.88M derived: sum of 2 quarters · filed 2012-02-29 | $47.10M derived: sum of 3 quarters · filed 2012-02-29 | $30.77M 10-K · filed 2012-02-29 |
| 2009-09-30 | $6.77M 10-Q · filed 2010-11-05 | $13.00M derived: sum of 2 quarters · filed 2010-11-05 | -$3.34M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $6.22M 10-Q · filed 2010-08-06 | -$10.11M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | -$6.13M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |